Hodgkin Lymphoma (HL): Diagnosis, Treatment and Side Effect Management (Participant)

Credit Available: ASWB, CABRN, ILNA, NP

 

Enroll in this Course

FREE

access until January 24, 2026 12:00 am

 

Enroll Now

Activity Description

This education program provides in-depth information about Hodgkin lymphoma (HL). Participants will gain thorough understanding of the subtypes of HL, the latest tests and techniques used to diagnose HL, up-to-date treatment options, what the goals of treatment are, and strategies to manage side effects, including surveillance of long-term and late effects. This program aims to empower participants with the knowledge and resources needed to make informed decisions about treating HL and providing patient and family education and support.

Time to Complete Activity: 1.50 hours

This course is available from:

July 25, 2024 until January 24, 2026

Course Instructors

David Awad, Pharm D, BCOP Speaker

Clinical Pharmacist Specialist, Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

Matthew Matasar, MD Speaker

Chief of Blood Disorders, Rutgers Cancer Institute of New Jersey,  New Brunswick, NJ

Tara McCabe, APN, AOCNP, MSN Speaker

Advanced Practice Nurse, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

Target Audience

Oncology nurse practitioners, nurses, and social workers involved in the care of patients with Hodgkin lymphoma (HL).

Course Content Level for Social Workers — all levels

Format: Non-interactive recorded webinar

Educational Objectives
After completing this activity, the participant should be better able to:

• • Describe the various subtypes of Hodgkin lymphoma (HL)
  • Identify tests used to diagnose disease and monitor treatment of HL
  • Explain the overarching goals of treatment for the subtypes of HL
  • Explain approved and emerging treatment options for HL, including stem cell transplantation, and the role of clinical trials
  • Describe strategies to manage treatment side effects as well as potential long-term and late effects of treatments for HL
  • Describe the roles of the pharmacist, the nurse, and the social worker in treating patients classical HL

Accreditation, Support and Credit

Nursing Continuing Professional Development

Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.5 continuing education contact hours through the California Board of Registered Nursing.

Social Worker Continuing Education

The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved as an ACE provider to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Regulatory boards are the final authority on courses accepted for continuing education credit. ACE provider approval period: 12/10/2023-12/10/2026. Social workers completing this course receive 1.5 clinical continuing education credits.

The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program. Social workers will receive 1.5 clinical CE contact hours for this activity.

Nurse Practitioner Continuing Education

This activity is approved for 1.5 contact hour(s) of continuing education (which includes 0.35 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 24086805. 

 

ILNA Recertification Points

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas: Care Continuum (OCN, CBCN, CPHON AOCNP), Foundations of Transplant (BMTCN), Oncology Nursing Practice (OCN), Psychosocial Dimensions of Care (AOCNP, CPHON, ONC, CBCN), Quality of Life (BMTCN), Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP), Transplant Process and Infusion (BMTCN), Treatment (OCN, CBCN, AOCNP, CPHON). 
Total points: 1.5*
*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum number of points that can be claimed in each subject area. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing.

Support Statement

There is no commercial support associated with this CE activity.

Provider

This activity is provided by The Leukemia & Lymphoma Society.

Disclosure of Conflicts of Interest Policy

All persons who may impact the content of a CE activity, including faculty and planners, are required to fully disclose current and recent financial relationships with commercial interests. A conflict of interest may be considered to exist if such a person has financial relationships with the grantor or any non-eligible entities (commercial interests) that may have a direct impact on the content of the program. Financial relationship is defined as being a shareholder, consultant, grant recipient, research participant, employee, and/or recipient of other financial or material support. Recent is defined as within the past 24 months. The participants in this CE activity must be made aware of any such financial relationship(s). This disclosure policy is intended to protect all parties involved from any potential conflict of interest that may arise.

Faculty Disclosures

David Awad, Pharm D, BCOP, has no financial relationships with ineligible companies.

Matthew Matasar, MD, has financial relationships with the following companies:

Advisory Board: Allogene, Epizyme, Genmab, Genentech, Kite, Merck, Regeneron

Consultant: AbbVie, AstraZeneca, Bristol Myers Squib, Epizyme, Novartis, Regeneron,   Roche, Pfizer

Research Support: ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Epizyme, Johnson & Johnson, Kite, Regeneron, Roche, Pfizer

Tara McCabe, APN, AOCNP, MSN, has no financial relationships with ineligible companies.

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from The Leukemia & Lymphoma Society do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

Lauren Berger, MPH, has a financial interest/relationship or affiliation in the form of:
Stock Ownership with Bristol Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc., Organon & Co., Pfizer Inc., and Viatris Inc.

All of the relevant financial relationships of individuals for this activity have been mitigated.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the accredited CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the activity posttest, evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. 

If you have questions regarding your certificate, please contact Nicole Dane via email at ndane@kimeglobal.com.

For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at ProfEducation@LLS.org.